Our commitment to support the social and economic development of the communities where we operate is built through partnerships with local stakeholders and the contribution of employees on behalf of ...

Whether you're living with atopic dermatitis (AD), commonly referred to as eczema, or looking after someone who is, you're in the right place. Change AD is here to make understanding and managing your ...

We chase the miracles of science to improve people’s lives. But we can’t do it alone. We work closely with healthcare professionals, patient advocates, governments and industry so we can have the ...

Third quarter 2024 results were reviewed by management during a conference call with the financial community on Friday October 25, 2024. The presentation was followed by a Q&A session. We’re proud to ...

Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and ...

The www.sanofi.com website (hereinafter the “site”) is owned and operated by SANOFI WINTHROP INDUSTRIE, belonging to Groupe Sanofi. The presentation and each of the elements, including trademarks, ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

Fourth quarter and full year 2023 results were reviewed by management during a live audio webcast with the financial community on February 1st, 2024. The presentation was followed by a Q&A session.

Established in Australia in 1980, with a global heritage that spans 100 years, we invest in the health of Australians by pioneering science and medicine across therapeutic areas including immunology, ...

The Sanofi of today is built on a heritage of turning the impossible into the possible for people and communities around the globe. In the last half century, Sanofi has grown into one of the world’s ...

Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma Recommendation based on IMROZ phase 3 study demonstrating Sarclisa in ...

For over 45 years, Sanofi has been at the forefront of combating meningococcal epidemics and in driving meningococcal vaccine innovation. Because no one should die or suffer from this ...